Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Information (Details)

v3.20.2
Stock-Based Compensation - Information (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Stock-Based Compensation    
Available for grant (in shares) 289,373  
Share-based compensation costs recognized $ 2,732 $ 1,712
Research and development expense    
Stock-Based Compensation    
Share-based compensation costs recognized 1,384 1,009
General and administrative expense    
Stock-Based Compensation    
Share-based compensation costs recognized $ 1,348 703
Options    
Stock-Based Compensation    
Number of options granted (in shares) 958,100  
Share-based compensation costs recognized $ 2,717 1,669
Weighted-average grant-date fair value 30,336  
Remaining unamortized expense $ 30,350  
Remaining unamortized expense period 1 year 8 months 12 days  
Options | BioXcel Corporation    
Stock-Based Compensation    
Share-based compensation costs recognized $ 15 $ 43